Special Issue "Fighting Radical Species in Human Health: Mitigating Radical Species with Natural and Synthetic Compounds"
A special issue of Antioxidants (ISSN 2076-3921).
Deadline for manuscript submissions: closed (30 September 2020).
Interests: probing diseases with small molecules; development of novel bioactive compounds with better pharmaceutical properties; medicinal chemistry; structure–activity relationship study; in silico screening for drug development; in vitro assays; ADME/PK assays; programmed cell death (e.g., Ferroptosis and apoptosis)
Special Issues and Collections in MDPI journals
Oxidative and nitrosative stress, also called the bad radical species, play a critical role in many diseases. For example, identifying new therapeutic strategies capable of modifying the course of neurodegenerative diseases is currently one of the major goals for researchers of this field. Developing novel pharmaceutical compounds bearing antioxidant properties will significantly enhance our understanding of their roles against the bad radical species in biological systems. It will help us to discover powerful compounds that eventually help patients suffering from diseases that involve radical species production. Eventually, these may lead to the design of novel therapeutic strategies, offer insight into neurodegenerative diseases, and lead to more effective treatments that will positively impact clinic outcomes.
There is evidence for an alternative therapeutic role for drugs with natural and non-natural antioxidative properties for efficient neuroprotection of oxidative stress in various models. Natural antioxidant compounds such as curcumin, resveratrol, and epigallocatechin-3-gallate are a class of compounds abundant in plants. Non-natural antioxidant compounds are a class of compounds such as butylated hydroxyanisole, tert-butylhydroquinonem and ferrostatin-1 (the first inhibitor of Ferroptosis cell death), created from a well-defined synthetic route.
We hope to stimulate our broad multidisciplinary investigators from neuroscience, chemical biology, plant biology, and drug discovery to provide a platform via this Special Issue that invites investigators to report their latest discoveries dealing with: (i) natural and non-natural small molecules, phenolic extracts; (ii) in vivo and/or in vitro mechanism of action of antioxidants, (iii) natural or synthetic antioxidants and their relevance to health and disease, (iv) relationships between antioxidant properties and human health promotion, and (v) protein aggregation and radical scavengers.
Dr. Rachid Skouta
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antioxidants is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Oxidative stress
- Radical species
- Neurodegenerative diseases (e.g., Alzheimer’s, Parkinson’s, Huntington, traumatic brain injury, stroke, epilepsy, and amyotrophic lateral sclerosis)
- Efficient synthesis of antioxidant compounds
- Cytoprotective phenolic extracts
- In vitro biochemical assays
- In vivo assays